Aaron Lorenzo

Aquavan's Efficacy Confirmed In Phase III Bronchoscopy Trial

March 21, 2007

By Aaron Lorenzo

Around and about the Beltway: House subcommittee advances genetic discrimination measure

March 20, 2007

By Aaron Lorenzo

Acadia Stock Doubles On Good Phase IIb Data In Schizophrenia

March 20, 2007

By Aaron Lorenzo

Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today)

Acadia Stock Doubles On Good Phase IIb Data In Schizophrenia

March 20, 2007

By Aaron Lorenzo

Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today)